AbbVie (ABBV) exec. says they anticipate aesthetics growth will remain challenged in 2026 and are focused on investing to stimulate the market
Importance
Level 1
- Expects 2026 Skyrizi revenue of USD 21.5bln and Rinvoq revenue of USD 10bln.
- Expects 2026 revenue of aesthetic sales to reach USD 5bln including Botox cosmetic revenue of USD 2.7bln.
- Expects Q1 adj. EPS between 2.97-3.01 (exp. 3.07); Net revenue approx. 14.7bln (exp. 14.85bln).
#ABBVIE INC#ABBV.US#EQUITIES#EU SESSION#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ABBVIE INC#ABBV#US EQUITIES